Item 1.01 Entry Into a Material Definitive Agreement.
On June 24, 2022, BioSig Technologies, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Laidlaw & Company (UK) Ltd. (the “Underwriter”), which was amended and restated on June 28, 2022 (the “Amended and Restated Underwriting Agreement”), relating to a best efforts public offering of 4,341,667 shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”). All of the Shares are being sold by the Company. The public offering price of the Shares is $0.75 per share. After the underwriting discounts, which includes a reduced discount with respect to certain Company-introduced investors, but before offering expenses payable by it, the Company expects to receive net proceeds from the offering of $3,030,880.23.
Pursuant to the Amended and Restated Underwriting Agreement, the Company has agreed to issue to the Underwriter or its designees warrants to purchase up to an aggregate 217,083 shares of Common Stock, or 5% of the number of Shares sold in the offering (the “Underwriter Warrants” and together with the Common Stock issuable upon exercise of the Underwriter Warrants, the “Underwriter Securities”). The Underwriter Warrants will be exercisable following the date of issuance and ending five years from the date of the execution of the Underwriting Agreement, at a price per share equal to $0.90 per share (120% of the public offering price per Share) and are exercisable on a “cashless” basis. The Company also agreed to reimburse the Underwriter for certain of their out-of-pocket expenses incurred in connection with the offering, including, among other things, the reasonable fees and expenses of counsel, which fees and expenses may not exceed $125,000.
The Shares will be issued pursuant to the Company’s shelf registration statement on Form S-3 (Registration Statement No. 333-251859) previously filed with the Securities and Exchange Commission (the “Commission”) and declared effective by the Commission on January 12, 2021. A preliminary prospectus supplement and final prospectus supplement and the accompanying prospectus relating to the offering have been filed with the Commission.
The Amended and Restated Underwriting Agreement contains customary representations and warranties, agreements and obligations, conditions to closing and termination provisions. The Amended and Restated Underwriting Agreement provides for indemnification by the Underwriter of the Company, its directors and certain of its executive officers, and by the Company of the Underwriter, for certain liabilities, including liabilities arising under the Securities Act of 1933, as amended, and affords certain rights of contribution with respect thereto. The legal opinion of Haynes and Boone, LLP relating to the legality of the issuance and sale of the Shares is attached as Exhibit 5.1 to this Current Report on Form 8-K.
The description of terms and conditions of the Underwriting Agreement, the Amended and Restated Underwriting Agreement and the form of Underwriter Warrant set forth herein do not purport to be complete and are qualified in their entirety by the full text of the Underwriting Agreement, the Amended and Restated Underwriting Agreement and the form of Underwriter Warrant, which are attached hereto as Exhibit 1.1, 1.2 and 4.1, respectively.